← Human Trials & Peer-Reviewed Studies
Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial
Plain-language guide to PMID 11926785 (2002): crossover randomized controlled trial study of NPH Insulin (isophane).
Key Facts
- PMID
- 11926785
- Journal
- Annals of internal medicine
- Year
- 2002
- Study type
- Randomized Controlled Trial
- Authors
- Fanelli CG et al. (6 authors)
- DOI
- 10.7326/0003-4819-136-7-200204020-00007
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at NPH Insulin (isophane).
Who Took Part
PubMed indexes the participants as adults, both men and women.
Randomized, open, two-treatment crossover trial in two 4-month periods.
Each patient was randomly assigned to one of two insulin regimens for 4 months and then switched to the other regimen for another 4 months.
How the Study Was Run
The design is described as randomized and crossover.
Random assignment meant chance, not the researchers, decided who got NPH Insulin (isophane) and who got the comparison, which limits bias.
In the crossover set-up each of the participants took both NPH Insulin (isophane) and the comparison in turn, acting as their own control.
A time span of 4 months appears in the methods.
University research center in Italy.
22 C-peptide-negative persons with type 1 diabetes mellitus (mean age [+/-SD], 29 +/- 3 years).
The two treatment regimens were 1) mixed treatment--a mixture of human regular and neutral protamine Hagedorn (NPH) insulin administered before dinner and 2) split treatment--human regular insulin administered at dinner and NPH insulin administered at bedtime.
Secondary end points were levels of fasting blood glucose and hemoglobin A1c and responses to experimental hypoglycemia.
What Was Measured
The subject headings attached to it are Analysis of Variance, Blood Glucose, Circadian Rhythm, Cognition Disorders, Diabetes Mellitus, Type 1, Hypoglycemia and Hypoglycemic Agents.
What This Means in Plain Language
The paper is a randomized and crossover study of NPH Insulin (isophane) over 4 months.
Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2002 (Annals of internal medicine), a journal based in United States.
More context: the NPH Insulin (isophane) compound page, all human trials.
Our Notes on the Compound
NPH Insulin (isophane): An intermediate-acting insulin made by combining insulin with protamine; also called isophane or NPH insulin (Humulin N, Novolin N).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.